Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia-Reference-Cited by-同舟云学术

Mutational spectrum and prognostic stratification of intermediate-risk acute myeloid leukemia

Published:2018-06-15 Issue:7-8 Volume:25 Page:207-213
ISSN:0929-1903
Container-title:Cancer Gene Therapy
language:en
Short-container-title:Cancer Gene Ther

Author:

Wu Sun,Dai Yifeng,Zhang Yuan,Wang Xiufeng,Wang Lihua,Ma Dong,Zhang Lingxiu,Pang Yifan,Jiao Yang,Niu Mingshan,Xu Kailin,Ke Xiaoyan,Shi Jinlong,Cheng Zhiheng^ORCID,Fu Lin^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/s41417-018-0028-z.pdf

Reference20 articles.

1. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell. 2014;14:275–91.

2. Mrózek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood. 2007;109:431–48.

3. Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.

4. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010;28:2739–47.

5. Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CA, Wouters BJ, et al. Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 2011;117:2469–75.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic significance ofKMT2A-PTD in patients with acute myeloid leukaemia: a systematic review and meta-analysis;BMJ Open;2023-02

2. Clinical Outcomes of Acute Myeloid Leukemia Patients Harboring the RUNX1 Mutation: Is It Still an Unfavorable Prognosis? A Cohort Study and Meta-Analysis;Cancers;2022-10-26

3. Delineation of Molecular Lesions in Acute Myeloid Leukemia Patients at Diagnosis: Integrated Next Generation Sequencing and Cytogenomic Studies;Genes;2021-05-30

4. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia;Journal of Translational Medicine;2019-05-20

5. Overexpression of PDK2 and PDK3 reflects poor prognosis in acute myeloid leukemia;Cancer Gene Therapy;2018-12-22